(NasdaqGM:GUTS), BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the second quarter 2025 and provide business updates on […]

(NASDAQ:BBSI), – Revenues and Gross Billings up 10% to $307.7 Million and $2.23 Billion –– Announces New $100 Million Stock Repurchase Program – VANCOUVER, Wash., Aug. 06, 2025 (GLOBE NEWSWIRE) — Barrett Business Services, Inc. (“BBSI” or the “Company”) (NASDAQ: BBSI), a leading provider of business management solutions, reported financial results for the second quarter

Cytek Biosciences Reports Second Quarter 2025 Financial Results GlobeNewswire August 06, 2025 FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) — Cytek(R) Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025. Second Quarter Highlights Total revenue for the second

Encore Capital Group Announces Second Quarter 2025 Financial Results GlobeNewswire August 06, 2025 Favorable purchasing conditions continue in U.S. market Global portfolio purchases up 32% to $367 million, including record $317 million in U.S. Global collections up 20% to record $655 million, including record $490 million in U.S. Estimated remaining collections (ERC) up 12% to

(NASDAQ:ECOR), Net sales of $7.4 million increased 20% vs. Q2'2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, 2025 Company to host a conference call and webcast today, August 6, 2025, at 4:30 p.m. EDT

AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance GlobeNewswire August 06, 2025 Dr. Tarnoff brings extensive executive and medical leadership experience from various organizations, including Tufts Medical Center and Medtronic. The Board thanks Lou Panaccio, its long-standing Board Chair, for

(NasdaqGM:ZNTL), DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $303.4 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, Aug. 06, 2025

Snail, Inc. Sets Second Quarter 2025 Conference Call for Wednesday, August 13, 2025 at 4:30 p.m. ET GlobeNewswire August 06, 2025 CULVER CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, will hold a conference call

MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance GlobeNewswire August 06, 2025 ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended

(NASDAQ:RDVT), BOCA RATON, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the quarter ended June 30, 2025. “We are pleased to report another strong quarter, delivering solid revenue growth and profitability while building on the momentum established early last